Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for COPD: A Randomized, Double-Blind, Multi-Center Parallel-Group Study.
2020
Rationale: In the Phase III, 52-week ETHOS trial in COPD (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause mortality versus glyc...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
21
Citations
NaN
KQI